Navigation Links
Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
Date:9/30/2008

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California to apply Lumiphore products in diagnostic tests for drugs of abuse.

Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4(TM) technology in current and future diagnostic tests of this type. Lumi4(TM) fluorescent metal-reporter compounds bring increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market through their excellent fade-resistant photophysical properties.

This is the third strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International (http://www.htrf.com/company/partners/) for the drug discovery research market and Echelon Biosciences Inc. (http://www.echelon-inc.com) for novel cancer assays involving phospholipid signaling and lipid-protein interactions.

The company today also announced the appointment of Dr. David J. Ecker to its board of directors. Dr. Ecker is Chief Scientific Officer and a founder of Ibis Biosciences and a co-founder and Vice President of Isis Pharmaceuticals. He brings to the board deep experience in successful biotech commercialization as well as specific technical expertise in detection and assay platforms.

Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor technology, and has authored more than 80 scientific publications and over 50 U.S. patents. His extensive publications span biosensor technology, infectiou
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... OSAKA, Japan, August 16 /PRNewswire-FirstCall/,-- Santhera Pharmaceuticals ... with a focus on neuromuscular diseases, and ... that the European Medicines Agency (EMEA) has ... (MAA) for Santhera,s lead compound,SNT-MC17 (INN: idebenone, ...
... Aug. 16 Cancer patients fraught with,flare-ups of ... assistance,in the form of a new easy-to-use oral ... quickly deliver pain medication. Cancer patients frequently ... cancer pain is characterized as continuous pain,present for ...
... 16 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... 2007 the,Nasdaq Listings Qualifications Department informed the Company ... below $50 million for 10,consecutive days, which is ... Market according to Marketplace Rule 4450(b)(1)(A). Nasdaq,also informed ...
Cached Biology Technology:European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6Novel Technology Breaks Through Cancer Pain 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... As researchers continue to examine the role ... people understand the differences among various ingredients used ... Association (CRA). Interchanging two distinctly different ingredients, such ... creates factually incorrect conclusions and misleads ,consumers. ...
... 4, 2009 Ben-Gurion University of the Negev engineers ... large nuclear reactors, making it unsuitable for use in ... form of the basic synthetic element found in commercial ... used for peaceful purposes. , This technique could help ...
... and very large reductions in greenhouse gas emissions compared ... messages from a series of expert papers on "The ... a special issue of Biofuels, Bioproducts and Biorefining ... which includes a comparative analysis of more than a ...
Cached Biology News:Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: